ClinicalTrials.gg
RecruitingNCT06950814Updated Apr 30, 2025

Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma

An observational study in Sarcomatoid Carcinoma, Liver Cancer and Adjuvant Therapy, sponsored by West China Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-30.

Sponsored by West China Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies in Carcinoma with a site in China — 37 open to participants now, 49 under way, 12 of them phase 3. Carcinoma · China.

Planned enrollment
16th of 19
50 · median 145
Started
2025
with 4 others
Observational
19 of 101
7 open now
Primary completion
2025-05
later than 12 of 48 live
Registered
86th of 101
by date
Lead sponsor
3 of 101
West China Hospital

Among the 101 studies in Carcinoma with a site in China, this one is the 16th largest by planned enrollment of the 19 observational ones that give a count, is one of 5 that started in 2025, is one of 19 observational ones, reaches primary completion later than 12 of the 48 other live ones, and was the 86th registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

37 of the 101 studies in Carcinoma with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Carcinoma with a site in China, or all of them as a file.
02

Study summary

In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.

03

Conditions studied

  • Sarcomatoid Carcinoma
  • Liver Cancer
  • Adjuvant Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The data was collected from patients who underwent liver resection and were diagnosed with PHSC pathologically. The data was collected from the division of Liver Surgery of West China Hospital, SCU from December 2018 to May 2023.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. patients who underwent liver resection
  2. patients' postoperative paraffin pathology and immunohistochemistry results were reviewed to identify those diagnosed with PHSC

Exclusion criteria

Exclusion Criteria:

  1. patients who received other anti-tumor treatments before surgery, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), radiation therapy (RT), and systemic therapy;
  2. patients diagnosed with other specific types of sarcomas;
  3. patients with concurrent other during the course of PHSC;
  4. patients who were lost to follow-up or lacked essential clinical data.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Primary hepatic sarcomatoid carcinoma patients who received adjuvant therapy

    Procedure: postoperative adjuvant therapy

  • Primary hepatic sarcomatoid carcinoma patients who did not receive adjuvant therapy

Interventions

  • Procedurepostoperative adjuvant therapy

    Given the rarity and high aggressiveness of PHSC, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines.

06

What researchers measure

Primary outcomes

  1. Disease-free survival

    Disease-free survival (DFS) was defined as the time from liver resection to disease recurrence or death from any cause.

    Time frame: From December 2018 to May 2023

Secondary outcomes

  1. Overall survival

    Overall survival (OS) was defined as the interval from liver resection to death or the last follow-up.

    Time frame: From December 2018 to May 2023

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for May 2025, 0 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2025
First posted
Apr 30, 2025
StartActual
Apr 5, 2025
Primary completionEst.
May 3, 2025
CompletionEst.
May 5, 2025
Last update
Apr 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06950814
Responsible party
Jiwei Huang (Clinical Professor, West China Hospital) — Principal investigator
First posted
Apr 30, 2025
Start date
Apr 5, 2025
Primary completion
May 3, 2025 (estimated)
Completion
May 5, 2025 (estimated)
Last update
Apr 30, 2025

Study contacts

Jiwei Huang Professor
Contact
huangjiwei@wchscu.cn
+86 18980606725

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion